Eszopiclone (Lunesta)

02/01/2010 - "In this Phase IV trial of older adults with insomnia, eszopiclone significantly improved patient-reported sleep and daytime function relative to placebo. "
01/01/2007 - "A decision analytical model was developed based on the reanalysis of a 6-month placebo-controlled trial, which demonstrated that eszopiclone 3mg significantly improved sleep and daytime function measures versus placebo in adults with primary insomnia. "
02/01/2006 - "In clinical trials, eszopiclone 3 mg significantly improved objective and subjective sleep measures in transient and chronic insomnia in adults. "
12/01/2012 - "In Japanese patients with primary insomnia, eszopiclone 2mg and 3mg significantly improved PSG-determined and patient-reported sleep latency and sleep maintenance relative to placebo."
07/01/2008 - "Sleep induction, maintenance, duration, and efficiency, as assessed by PSG, were significantly improved following eszopiclone treatment in patients with insomnia. "

12/01/2014 - "On further analysis there was a significant improvement in the working memory test, letter-number span component of MATRICS (mean=9.8±9.2, z=-2.00, p=0.045) only for subjects with schizophrenia on eszopiclone. "
12/01/2014 - "Sleep remained improved during single-blind placebo phase after eszopiclone was stopped, but the working memory improvement in patients with schizophrenia was not durable. "
01/01/2018 - "Eszopiclone for persistent negative symptoms in schizophrenia - An unintended N-of-1 study."
09/01/2013 - "The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial."
12/01/2020 - "Twenty-six medicated schizophrenia outpatients and 29 healthy controls were randomly assigned to have a placebo or eszopiclone (3 mg) sleep visit first. "

03/01/2010 - "Eszopiclone is effective for the treatment of insomnia in patients with insomnia and comorbid major depressive disorder (MDD). "
03/01/2010 - "Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder."
01/01/2005 - "Preliminary results from a completed phase IIIB/IV trial report that eszopiclone in combination with fluoxetine significantly improved sleep parameters among patients with insomnia and co-existing major depressive disorder. "
06/01/2006 - "Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder."
05/01/2022 - "We investigated the utility of switching from benzodiazepines to suvorexant or eszopiclone to manage benzodiazepine-unresponsive insomnia in patients with major depressive disorder (MDD) in a randomized, open-label study. "

09/01/2018 - " efficacy of CBT-I combined with eszopiclone in the treatment of sleep disorders in ICU transferred out patients was better than eszopiclone."
01/01/2022 - "Eszopiclone can effectively improve the quality of sleep and cognitive function in elderly patients with AD and sleep disorder."
01/01/2023 - "Effectiveness of eszopiclone in treating sleep disorders in elderly people with hypertension and the effect on patients' sleep quality."
01/01/2022 - "To investigate the effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer's disease (AD) and sleep disorders. "
01/01/2022 - "Effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer's disease and sleep disorder: A randomized controlled trial."

10/01/2014 - "A 12-week, randomized, double-blind, placebo-controlled trial evaluated efficacy and safety of high- or low-dose eszopiclone (1 or 2 mg in children aged 6-11 years, 2 or 3 mg in children ages 12-17 years), given every evening, in 486 patients with ADHD-related insomnia. "
10/01/2014 - "Eszopiclone (up to 3 mg) failed to reduce latency to persistent sleep on polysomnography after 12 weeks in children aged 6 to 17 years with ADHD-related insomnia. "
10/01/2014 - "To evaluate efficacy and safety of eszopiclone compared with placebo in children and adolescents with insomnia associated with attention-deficit/hyperactivity disorder (ADHD). "
10/01/2014 - "Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder."
01/01/2019 - "Single randomized controlled trials of zolpidem and eszopiclone in children with attention-deficit/hyperactivity disorder (ADHD) showed no improvement in sleep or ADHD ratings. "